In what may be one of the more questionable mergers in biotech history, AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc., two firms that have little in common besides recently launched products that have underperformed commercially, agreed to combine in an all-stock deal valued at about $686 million.